Blog Archive

Research News

“Added sensitivity of component-resolved diagnosis in hymenoptera venom-allergic patients with elevated serum tryptase and/or mastocytosis.” Michel J, Brockow K, Darsow U, Ring J, Schmidt-Weber CB, Grunwald T, Blank S, Ollert M.
Allergy. 2016 Feb 2. doi: 10.1111/all.12850 Pubmed Link

The new publication co-authored by PLS-Design colleagues evaluates the advantages of component-resolved diagnosis for mastocytosis patients. Approximately 5% of patients suffering anaphylactic reactions due to strong allergy against hymenoptera venom allergy show an elevated baseline of serum tryptase (sBT) and/or mastocytosis.
The sIgE sensitization pattern and diagnostic sensitivity in hymenoptera venom-allergic patients with elevated sBT levels and/or mastocytosis was tested with a panel of recombinant yellow jacket and honeybee venom allergens on a widely used IgE immunoassay platform.
It could be shown that for these high risk patients with elevated sBT levels and/or mastocytosis the use of molecular components and decreasing the threshold sIgE level to 0.1 kUA /L may be needed to avoid otherwise undetectable IgE to hymenoptera venom extracts in about 8% of such patients.

The publication clearly proofs the potential value of recombinant allergens in allergy diagnostics, especially for high risk patients. PLS-Design has patent-protected several hymenoptera venom allergens.

See PLS-Design’s information about Companion Diagnostics (CDx) andRecombinant Allergens here.

27 Feb 2013

Omalizumab for urticaria study status

By There are no tags 0 comments

In the online edition of the “New England Journal of Medicine” the first results from the Novartis Phase III study (ASTERIA II) of the use of omalizumab for chronic sponaneous urticaria (CSU) have been published. The data were also presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting in San Antonio, Texas, USA.
Novartis claims that the results indicate that Omalizumab is a potentially valuable treatment option for moderate to severe refractory chronic idiopathic or spontaneous urticaria (CIU/CSU). Novartis aims at a regulatory submission for this new application of Omalizumab in 2013.

See NEJM site for article:
Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, Agarwal S, Doyle R, Canvin J, Kaplan A, and Casale T.

See Novartis press release here.

IgE-Quantification can be used to monitor an anti-IgE therapy, like omalizumab treatment.
For example, the amount of remaining free IgE under omalizumab treatment can be quantified using PLS-Design‘s IgE-AviQuant molecule. Read more here!

Copyright 2018 by PLS-Design GmbH